News & Events
New Data Suggesting that ChemGenex's Omacetaxine Can Eradicate Leukemic
27 / 03 / 2009
-- New Data Published in Leukemia Showed 90% Kill of Leukemic Stem Cells and Prolonged Survival in Mice with Resistant CML - Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are…
Xenome - Addition to US patent portfolio for Xen2174
23 / 03 / 2009
Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)". This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, theâ?¦
Arana - Shareholder Update - Bid from Cephalon
10 / 03 / 2009
Dear Arana Shareholder, I am writing to you to ensure you are up to date with several important developments for Arana Therapeutics Limited ("Arana"). As you may already be aware, on 27 February 2009 Cephalon, Inc. (Nasdaq: CEPH) announced that its wholly-ownedâ?¦
Cephalon announces intention to offer $1.40 per share for Arana
27 / 02 / 2009
Cephalon, Inc. (Nasdaq: CEPH) today announced that its wholly-owned subsidary, Cephalon International Holdings, Inc., intends to make a cash takeover offer for all of the shares in Arana Therapeutics Limited which it does not already own (ASX: AAH) ("Arana") at a minimum price of $1.40 per…
STRATEGIC RELATIONSHIP UPDATE
18 / 02 / 2009
CogState Ltd (ASX:CGS) and United BioSource Corporation (UBC) announced today that they will not renew the strategic relationship the two companies initiated in 2008 to co-market and co-deliver CogState's ClinicalTrials software for computerized cognitive testing in clinical trials. …
Positive Results for Peplin's Phase IIb AK Trial
08 / 01 / 2009
Met primary efficacy endpoint with statistically significant complete clearance rate of AK lesions vs. vehicle Reduction in overall lesion count in all active treatment groups Well-tolerated, rapidly resolving local skin responses at all concentrations and durations …
Xenome Grants MedImmune License to xdiscoverT Venom Peptide Library
08 / 01 / 2009
Xenome Limited ("Xenome") today announced it has executed a research licence agreement with MedImmune LLC (MedImmune"), a wholly owned subsidiary of AstraZeneca. Under the partnership MedImmune will gain access to Xenome's xdiscoverT venom peptide library to exclusively…
The Plantronics Discovery 925 Wins 7B Labs'' Premium Bluetooth
07 / 01 / 2009
Plantronics Discovery 925 beats competitors from Jawbone, BlueAnt and Motorola in an independent consumer research study performed by 7B Labs. 7B Labs announced today that the Plantronics Discovery 925 has won its Premium Bluetooth Headset Challenge, beating out the Aliph…
NUON THERAPEUTICS INC. NAMES MICHAEL M. KITT, M.D.,
05 / 01 / 2009
Nuon Therapeutics, Inc., a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, today announced the appointment of Michael M. Kitt, M.D., to the position of Chief Medical Officer. "Dr. Kitt is an…